Atossa Therapeutics Inc
NASDAQ:ATOS
Balance Sheet
Balance Sheet Decomposition
Atossa Therapeutics Inc
Current Assets | 87.1m |
Cash & Short-Term Investments | 84m |
Other Current Assets | 3.1m |
Non-Current Assets | 4m |
Long-Term Investments | 1.7m |
Other Non-Current Assets | 2.3m |
Current Liabilities | 5.3m |
Accounts Payable | 1.2m |
Accrued Liabilities | 2.3m |
Other Current Liabilities | 1.8m |
Balance Sheet
Atossa Therapeutics Inc
Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
9
|
4
|
3
|
7
|
10
|
13
|
40
|
136
|
111
|
88
|
|
Cash Equivalents |
9
|
4
|
3
|
7
|
10
|
13
|
40
|
136
|
111
|
88
|
|
Total Receivables |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
|
Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Assets |
1
|
1
|
0
|
0
|
1
|
1
|
3
|
4
|
7
|
4
|
|
Total Current Assets |
9
|
4
|
3
|
8
|
12
|
14
|
43
|
141
|
118
|
92
|
|
PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Intangible Assets |
2
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
2
|
|
Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
|
Total Assets |
12
N/A
|
6
-47%
|
4
-34%
|
8
+100%
|
12
+43%
|
15
+24%
|
43
+195%
|
141
+230%
|
124
-13%
|
96
-22%
|
|
Liabilities | |||||||||||
Accounts Payable |
1
|
1
|
0
|
0
|
0
|
0
|
2
|
2
|
3
|
1
|
|
Accrued Liabilities |
1
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
3
|
3
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
1
|
0
|
0
|
0
|
1
|
0
|
13
|
0
|
0
|
2
|
|
Total Current Liabilities |
2
|
3
|
1
|
1
|
3
|
1
|
16
|
3
|
6
|
5
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Liabilities |
2
N/A
|
3
+9%
|
1
-60%
|
1
+20%
|
3
+142%
|
1
-55%
|
16
+1 108%
|
3
-80%
|
6
+81%
|
5
-7%
|
|
Equity | |||||||||||
Common Stock |
0
|
0
|
0
|
1
|
4
|
2
|
9
|
23
|
23
|
23
|
|
Retained Earnings |
35
|
51
|
57
|
65
|
77
|
94
|
112
|
129
|
156
|
186
|
|
Additional Paid In Capital |
45
|
55
|
60
|
72
|
82
|
105
|
130
|
244
|
251
|
256
|
|
Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Total Equity |
10
N/A
|
4
-61%
|
3
-16%
|
7
+123%
|
9
+28%
|
13
+50%
|
27
+106%
|
138
+408%
|
118
-15%
|
91
-23%
|
|
Total Liabilities & Equity |
12
N/A
|
6
-47%
|
4
-34%
|
8
+100%
|
12
+43%
|
15
+24%
|
43
+195%
|
141
+230%
|
124
-13%
|
96
-22%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
0
|
0
|
0
|
3
|
6
|
9
|
48
|
127
|
127
|
125
|
|
Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|